Natural xanthones as modulators of the Nrf2/ARE signaling pathway and potential gastroprotective agents

Natalie Vivien Gunter1, Soek Sin Teh2, Ibrahim Jantan3

  • 1School of Biosciences, Faculty of Health and Medical Sciences, Taylor's University, Subang Jaya, Malaysia.

Phytotherapy Research : PTR
|February 19, 2024
PubMed

Insights

Natural compounds called xanthones show promise for treating gastric inflammatory diseases by reducing oxidative stress. They activate the Nrf2/ARE pathway, offering a safer alternative to current treatments.

Area of Science:

  • Pharmacology
  • Natural Products Chemistry
  • Gastroenterology

Background:

  • Oxidative stress is a key factor in gastric inflammatory diseases (GID).
  • Current treatments for GID have limitations and potential adverse effects.
  • There is a need for novel gastroprotective agents that target oxidative stress via cellular defense pathways.

Purpose of the Study:

  • To explore xanthones as potential gastroprotective agents.
  • To investigate the role of xanthones in modulating the Nrf2/ARE signaling pathway.
  • To identify specific xanthone compounds with high potential for GID treatment.

Main Methods:

  • Literature review of xanthone's effects on oxidative stress and GID.
  • Analysis of studies on xanthone derivatives modulating the Nrf2/ARE pathway in vitro and in vivo.
  • Identification of natural xanthones exhibiting gastroprotective actions.

Main Results:

  • Thirteen natural xanthones were identified as modulators of the Nrf2/ARE signaling pathway.
  • Mangiferin, α-mangostin, and γ-mangostin demonstrated significant in vivo gastroprotective effects.
  • Xanthones exhibit antioxidant, anti-inflammatory, and cytoprotective properties relevant to GID.

Conclusions:

  • Xanthones, particularly mangiferin, α-mangostin, and γ-mangostin, are promising candidates for GID treatment.
  • Modulation of the Nrf2/ARE pathway is a key mechanism for xanthone's gastroprotective effects.
  • Further research is recommended to validate these findings and develop new therapies.